The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression
Abstract
Objectives: Anxiety in major depression is associated with increased morbidity. The antidepressant, agomelatine, which acts as an agonist at melatonin MT 1 and MT 2 receptors and as an antagonist at serotonin 5‐HT 2C receptors, has demonstrated efficacy and safety in both major depression and generalized anxiety disorder. Here, we investigated the efficacy of agomelatine in anxious depression. Methods: Data from three placebo‐controlled short‐term trials of agomelatine and three comparative studies of agomelatine versus fluoxetine, sertraline, and venlafaxine were pooled. Effects of agomelatine on anxiety symptoms were assessed with the Hamilton Anxiety Rating Scale in four studies (one vs placebo and three vs active comparator) and with the Hamilton Depression Rating Scale (HAMD) anxiety subscore in all six studies. Anxiolytic and antidepressant efficacies of agomelatine were assessed in patients with more severe anxiety symptoms at baseline (score ≥5 on HAMD anxiety subscore). Results: Agomelatine had a significantly greater effect on anxiety symptoms than both placebo and a number of comparator antidepressants. In more anxious depressed patients, agomelatine had a significantly greater effect on anxiety and depressive symptoms than both placebo and comparator antidepressants. Conclusion: Once‐a‐day oral agomelatine is a new, efficacious alternative option for the treatment of anxiety in patients with major depression. Copyright © 2013 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Quality-of-Life Impairment in Depressive and Anxiety Disorders
Rapaport, M. H., Clary, C., Fayyad, R., & Endicott, J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1171 · Cited by 914 · cited 2×
“Depression is associated with reduced quality of life (Rapaport et al., 2005), as well as impaired function at home and at work, where it is associated with both absenteeism and presenteeism (loss of productivity while attending work when unwell; Sanderson et al., 2007).”
BackgroundFava, M., Rush, A. J., Alpert, J. E., Carmin, C. N., Balasubramani, G., Wisniewski, S. R., Trivedi, M. H., Biggs, M. M., & Shores-Wilson, K. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605101304 · Cited by 183
Goldberg, D., & Fawcett, J. (2012) · Depression and Anxiety · doi:10.1002/da.21939 · Cited by 155
Melatonin analogues as agonists and antagonists in the circadian system and other brain areas
Ying, S.-W., Rusak, B., Delagrange, P., Mocaër, E., Renard, P., & Guardiola-Lemaître, B. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00684-2 · Cited by 114
Stein, D. J., Ahokas, A., Albarran, C., Olivier, V., & Allgulander, C. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07493 · Cited by 94
Self-citation
Cited by
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“, 2010) with a recent study suggesting agomelatine may have superior efficacy (Stein et al., 2013).”
BackgroundMillan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Circadian depression: A mood disorder phenotype
Carpenter, J. S., Crouse, J. J., Scott, E. M., Naismith, S. L., Wilson, C., Scott, J., Merikangas, K. R., & Hickie, I. B. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.045 · Cited by 114
Ghajar, A., Neishabouri, S., Velayati, N., Jahangard, L., Matinnia, N., Haghighi, M., Ghaleiha, A., Afarideh, M., Salimi, S., Meysamie, A., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0042-116159 · Cited by 110
Neuropharmacological classification of antidepressant agents based on their mechanisms of action
Fasipe, O. (2018) · Archives of Medicine and Health Sciences · doi:10.4103/amhs.amhs_7_18 · Cited by 80
Agomelatine in Generalized Anxiety Disorder: An Active Comparator and Placebo-Controlled Study
Stein, D. J., Ahokas, A., Márquez, M. S., Höschl, C., Oh, K. S., Jarema, M., Avedisova, A. S., Albarran, C., & Olivier, V. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08433 · Cited by 67
Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
Levitan, M., Papelbaum, M., & E Nardi, A. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s67470 · Cited by 25
Metadata
- Authors
- Stein, D. J., Picarel‐Blanchot, F., & Kennedy, S. H.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2013-03
- Volume
- 28
- Issue
- 2
- Pages
- 151-159
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W1558149471
- Cited by
- 224
- References
- 6
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.